These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 25944653)
21. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427 [TBL] [Abstract][Full Text] [Related]
22. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features. Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326 [TBL] [Abstract][Full Text] [Related]
23. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205 [TBL] [Abstract][Full Text] [Related]
24. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. von Deimling A; Korshunov A; Hartmann C Brain Pathol; 2011 Jan; 21(1):74-87. PubMed ID: 21129061 [TBL] [Abstract][Full Text] [Related]
25. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768 [TBL] [Abstract][Full Text] [Related]
27. Updates in prognostic markers for gliomas. Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261 [TBL] [Abstract][Full Text] [Related]
28. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139 [TBL] [Abstract][Full Text] [Related]
29. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542 [TBL] [Abstract][Full Text] [Related]
30. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748 [TBL] [Abstract][Full Text] [Related]
31. Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. Robertson T; Koszyca B; Gonzales M Pathology; 2011 Feb; 43(2):88-92. PubMed ID: 21233669 [TBL] [Abstract][Full Text] [Related]
32. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591 [TBL] [Abstract][Full Text] [Related]
33. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas. Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710 [No Abstract] [Full Text] [Related]
34. [Genetic alterations and biomarkers for glioma]. Nagane M Brain Nerve; 2012 May; 64(5):537-48. PubMed ID: 22570067 [TBL] [Abstract][Full Text] [Related]
36. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825 [TBL] [Abstract][Full Text] [Related]
37. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176 [TBL] [Abstract][Full Text] [Related]
38. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers. Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231 [TBL] [Abstract][Full Text] [Related]
39. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
40. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote. Otani R; Uzuka T; Ueki K Jpn J Clin Oncol; 2017 Jan; 47(1):2-6. PubMed ID: 27799281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]